Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently amended) A pharmaceutical formulation for the controlled release of a therapeutic peptide or a salt of the peptide, said formulation comprising: ~~thereof,~~

a peptide comprising ~~which peptide has the sequence~~ (SEQ ID NO: 7)

pyro Glu-His-Trp-Ser-Xaa^1-Gly-Xaa^2-Xaa^3-Pro-Gly-NH_2, or a salt thereof,

wherein Xaa^1 is His or Tyr,

Xaa^2 is Trp or Leu, and

Xaa^3 is Tyr or Arg,

provided that when Xaa^1 is Tyr and Xaa^2 is Leu, then Xaa^3 is not Arg,

and ~~which formulation further comprises~~ a pharmaceutically acceptable biodegradable polymer.

Claim 2. (Currently amended) The pharmaceutical formulation ~~composition~~ according to Claim 1, wherein the peptide comprises ~~is~~ (SEQ ID NO: 6)

pyroGlu-His-Trp-Ser-His-Gly-Trp-Tyr-Pro-Gly-NH_2.

Claim 3. (Currently amended) The pharmaceutical formulation according to Claim 1, wherein the polymer comprises ~~is~~ a polymer of a hydroxyl derivative of a carboxylic acid, a polymer of an amino derivative of a carboxylic acid, or a copolymer of ~~such~~ the carboxylic acid derivatives.

Claim 4. (Currently amended) The pharmaceutical formulation according to Claim 3, wherein the polymer comprises ~~is~~ a polymer of glycolic acid, a polymer of lactic acid, or a copolymer of glycolic and lactic acid ~~such derivatives~~.

Claim 5. (Currently amended) The pharmaceutical formulation according to Claim 1, wherein the peptide is microencapsulated by the polymer.

Claim 6. (Currently amended) A method for treating a human pathology comprising administering ~~the treatment of a human medical condition, which method comprises the administration~~ to an individual in need of said ~~such~~ treatment ~~of~~ a therapeutically effective amount of the pharmaceutical formulation ~~a controlled release formulation of a peptide~~ according to Claim 1 ~~any of the preceding claims~~.

Claim 7. (Currently amended) ~~A~~ The pharmaceutical formulation according to claim 1 for treatment of, or for protection against, a disorder of bone growth ~~or disorder of prostate growth~~.

Claim 8. (Currently amended) ~~The use of peptide or salt as defined in claim 1, together with a pharmaceutically acceptable biodegradable polymer, for the preparation of~~ A method for preparing a controlled release medicament for the treatment of, or protection against, a disorder of bone growth ~~or prostate growth~~ comprising:

providing a peptide comprising (SEQ ID NO: 7)

pyro Glu-His-Trp-Ser-Xaa^1-Gly-Xaa^2-Xaa^3-Pro-Gly-NH_2, or a salt thereof,

wherein Xaa^1 is His or Tyr,

Xaa^2 is Trp or Leu, and

Xaa^3 is Tyr or Arg,

provided that when Xaa^1 is Tyr and Xaa^2 is Leu, then Xaa^3 is not Arg, and

incorporating the peptide or salt into a matrix of a pharmaceutically acceptable biodegradable polymer or encapsulating the peptide or salt with a pharmaceutically acceptable biodegradable polymer.

Claim 9. (Currently amended) ~~A use~~ The method according to claim 8, wherein said polymer ~~is~~ comprises:

(a) a polymer of a hydroxy derivative of a carboxylic acid, a polymer of an amino derivative of a carboxylic acid, or a copolymer of the carboxylic acid ~~such~~ derivatives, or

(b) a polymer of glycolic acid, a polymer of lactic acid, or a co-polymer of lactic and glycolic acid~~s~~.

Claim 10. (Currently amended) ~~A use~~ The method according to claim 8, wherein said disorder is selected from the group consisting of age-related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis~~, benign prostatic hyperplasia and prostate cancer~~.

Claim 11. (Currently amended) ~~A~~ The pharmaceutical formulation according to claim 7, ~~for the treatment of, or protection against,~~ wherein said disorder is selected from the group consisting of ~~selected form~~ age-related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis~~, benign prostatic hyperplasia and prostate cancer~~.

Claim 12. (Currently amended) ~~A~~ The method according to claim 6, wherein the human pathology comprises ~~for treating or protecting against~~ a human disorder of bone growth ~~or of~~

~~prostate growth, which method comprises the administration to an individual in need of such treatment or protection of a therapeutically effective amount on a formulation according to claim 1.~~

Claim 13. (Currently amended) ~~A~~ The method according to claim 12, wherein said disorder is selected from the group consisting of age-related osteoporosis, osteoporosis associated with post-menopausal hormone status, primary and secondary hyperparathyroidism, disuse osteoporosis, diabetes-related osteoporosis, and glucocorticoid-related osteoporosis~~, benign prostatic hyperplasia and prostate cancer~~.